147 related articles for article (PubMed ID: 16879214)
1. Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records.
Osman A; Enström C; Arbring K; Söderkvist P; Lindahl TL
J Thromb Haemost; 2006 Aug; 4(8):1723-9. PubMed ID: 16879214
[TBL] [Abstract][Full Text] [Related]
2. [Haplogroup analysis of vitamin-K epoxide reductase (VKORC1) gene: novel element in the optimization of anticoagulant therapy].
Sipeky C; Melegh B
Orv Hetil; 2008 Sep; 149(39):1839-44. PubMed ID: 18805772
[TBL] [Abstract][Full Text] [Related]
3. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
Molden E; Okkenhaug C; Ekker Solberg E
Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
[TBL] [Abstract][Full Text] [Related]
4. Inter-individual differences in baseline coagulation activities and their implications for international normalized ratio control during warfarin initiation therapy.
Ichimura Y; Takahashi H; Lee MT; Shiomi M; Mihara K; Morita T; Chen YT; Echizen H
Clin Pharmacokinet; 2012 Dec; 51(12):799-808. PubMed ID: 23018470
[TBL] [Abstract][Full Text] [Related]
5. Genetic determinants of response to warfarin during initial anticoagulation.
Schwarz UI; Ritchie MD; Bradford Y; Li C; Dudek SM; Frye-Anderson A; Kim RB; Roden DM; Stein CM
N Engl J Med; 2008 Mar; 358(10):999-1008. PubMed ID: 18322281
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1.
Harrington DJ; Underwood S; Morse C; Shearer MJ; Tuddenham EG; Mumford AD
Thromb Haemost; 2005 Jan; 93(1):23-6. PubMed ID: 15630486
[TBL] [Abstract][Full Text] [Related]
7. Plasma S/R ratio of warfarin co-varies with VKORC1 haplotype.
Osman A; Enström C; Lindahl TL
Blood Coagul Fibrinolysis; 2007 Apr; 18(3):293-6. PubMed ID: 17413769
[TBL] [Abstract][Full Text] [Related]
8. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.
Rieder MJ; Reiner AP; Gage BF; Nickerson DA; Eby CS; McLeod HL; Blough DK; Thummel KE; Veenstra DL; Rettie AE
N Engl J Med; 2005 Jun; 352(22):2285-93. PubMed ID: 15930419
[TBL] [Abstract][Full Text] [Related]
9. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment.
Watzka M; Geisen C; Bevans CG; Sittinger K; Spohn G; Rost S; Seifried E; Müller CR; Oldenburg J
J Thromb Haemost; 2011 Jan; 9(1):109-18. PubMed ID: 20946155
[TBL] [Abstract][Full Text] [Related]
10. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
11. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.
Lee SC; Ng SS; Oldenburg J; Chong PY; Rost S; Guo JY; Yap HL; Rankin SC; Khor HB; Yeo TC; Ng KS; Soong R; Goh BC
Clin Pharmacol Ther; 2006 Mar; 79(3):197-205. PubMed ID: 16513444
[TBL] [Abstract][Full Text] [Related]
12. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.
Yuen E; Gueorguieva I; Wise S; Soon D; Aarons L
J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):3-24. PubMed ID: 19941044
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients.
Shrif NE; Won HH; Lee ST; Park JH; Kim KK; Kim MJ; Kim S; Lee SY; Ki CS; Osman IM; Rhman EA; Ali IA; Idris MN; Kim JW
Eur J Clin Pharmacol; 2011 Nov; 67(11):1119-30. PubMed ID: 21590310
[TBL] [Abstract][Full Text] [Related]
14. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans.
Takahashi H; Wilkinson GR; Nutescu EA; Morita T; Ritchie MD; Scordo MG; Pengo V; Barban M; Padrini R; Ieiri I; Otsubo K; Kashima T; Kimura S; Kijima S; Echizen H
Pharmacogenet Genomics; 2006 Feb; 16(2):101-10. PubMed ID: 16424822
[TBL] [Abstract][Full Text] [Related]
15. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.
Veenstra DL; You JH; Rieder MJ; Farin FM; Wilkerson HW; Blough DK; Cheng G; Rettie AE
Pharmacogenet Genomics; 2005 Oct; 15(10):687-91. PubMed ID: 16141794
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
17. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Limdi NA; Beasley TM; Crowley MR; Goldstein JA; Rieder MJ; Flockhart DA; Arnett DK; Acton RT; Liu N
Pharmacogenomics; 2008 Oct; 9(10):1445-58. PubMed ID: 18855533
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of VKORC1 and CYP2C9 gene polymorphisms in Indian population and its effect on warfarin response.
Shalia KK; Doshi SM; Parikh S; Pawar PP; Divekar SS; Varma SP; Mehta R; Doctor T; Shah VK; Saranath D
J Assoc Physicians India; 2012 Dec; 60():34-8. PubMed ID: 23781667
[TBL] [Abstract][Full Text] [Related]
19. Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.
Li C; Schwarz UI; Ritchie MD; Roden DM; Stein CM; Kurnik D
Blood; 2009 Apr; 113(17):3925-30. PubMed ID: 19074728
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
